QIAGEN N.V.: QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer

EQT Private Equity proposed an all-cash takeover offer for QIAGEN. EQT XI plans to invest 10-15% of its €23B target fund. Details on price, terms, and approvals are pending.

QIAGEN and EQT Private Equity agreed on an all-cash takeover offer of EUR46.50 per share, a 40.3% premium. QIAGEN's boards support the deal, valuing the company at EUR10.8 billion. The transaction is expected to close in mid-2027, subject to regulatory approvals and a minimum 50% shareholder acceptance.

QIAGEN and EQT Private Equity agreed on an all-cash takeover offer for QIAGEN shares at €46.50 per share, a 40.3% premium. The deal, valued at €10.8B, is supported by QIAGEN's boards and expected to close in mid-2027, subject to approvals and a 50% acceptance threshold.

QIAGEN reported Q3 2026 net sales of $548M and adjusted EPS of $0.65. The company suspended its full-year outlook due to a pending transaction with EQT Private Equity and will announce full Q3 results on November 4, 2026. QIAGEN provides molecular analysis solutions and serves over 500,000 customers globally.

QIAGEN (QGEN) accepted a €10.8B all-cash takeover offer from EQT Private Equity at €46.50 per share, a 40.3% premium over its July 8, 2026 closing price. The deal, subject to regulatory approvals, is expected to close in mid-2027. QIAGEN's boards unanimously approved the transaction, which will delist its shares from the Frankfurt and NYSE exchanges post-closing.

QIAGEN reported preliminary Q3 2026 net sales of $548M and adjusted diluted EPS of $0.65. The company suspended its full-year 2026 outlook due to a pending EQT Private Equity transaction.